---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-116853"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:32:39.292816+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics PRT3789 Phase 1 interim data: 4 PRs; DAC program preclinical proof-of-concept

## Summary
- Interim Phase 1 results: 4 confirmed partial responses (2 esophageal, 2 NSCLC) out of 26 evaluable SMARCA4 loss-of-function patients.
- PRT3789 generally well-tolerated; no dose-limiting toxicities or drug-related SAEs; higher doses (≥212 mg) show deeper SMARCA2 degradation.
- Combination with docetaxel shows acceptable safety profile; preclinical data show synergy with chemo in SMARCA4-mutant NSCLC models.
- First preclinical proof-of-concept for SMARCA2/4 dual degrader antibody conjugates (DACs): anti-PSMA DACs show efficacy and tolerability in xenograft models.

## SEC filing metadata
- accession: 0000950170-24-116853
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017024116853/0000950170-24-116853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017024116853/prld-20241024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-116853
- JSON: https://secwatch.observer/filing/0000950170-24-116853.json
- Plain text: https://secwatch.observer/filing/0000950170-24-116853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.